PAVM News and Press, PAVmed Inc. From 11/16/21

PAVmed (NASDAQ:PAVM) shares have lost ~6.7% in the post-market after the company disclosed preliminary financial results for the third quarter of 2021 that fell short of Street forecasts. The company has recorded $0.20M in revenue for the quarter, while the consensus revenue es...

Conference call to be held today at 4:30 PM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) (...

BEST, DLB, DLO, GSM, DADA, PAVM, SBLK, STNE, TTCF, VREX For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Tuesday's close

Patients in Denver, Salt Lake City, and Las Vegas metropolitan areas now have access to a rapid, non-invasive, office-based test to detect esophageal precancer before it progresses to deadly esophageal cancer Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) ...

Company conference call and webcast at 4:30PM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ ), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD), a cancer prevention medical diagnostics ...

Panelists discussed Veris’ vision and strategy to transform cancer care and join the current digital health revolution PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage m...

BioTech Breakthrough’s Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of...

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, and its digital health subsidiary Veris Health (“Veris”) today announced the appointment of Silicon Valley technology executive ...

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the appointment of highly accomplished molecular biologist Suman...

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the appointment of highly accomplished molecular biologist Suman...